Category Archives: Bioprocessing

Q Therapeutics’ and Invitrogen’s Symbiotic Relationship

Posted on February 25, 2008 by jrowley

Q Therapeutics, a cell therapy company focusing on neural applications, recently announced a $15M series B financing that included funding from multiple venture capital (VC) groups as well as biotech tools provider Invitrogen. Q’s lead product, Q-Cells™, is an allogeneic … Continue reading →

Posted in adult stem cell, Bioprocessing, Clinical Trials, Company Profiles, Manufacturing, MS, Neural Repair, Q Therapeutics, Regenerative Medicine, stem cells | Tagged , , , | 2 Comments

Cytori Announces Progress in Cardiac Regeneration Clinical Studies

Posted on February 1, 2008 by jrowley

Cytori Therapeutics announced that they have enrolled their first two patients in an acute myocardial infarction clinical trial using adipose-derived cells prepared using their Celution™ device. The Celution™ device is an automated, tissue processing unit that isolates cells from adipose … Continue reading →

Posted in adult stem cell, autologous, Bioprocessing, cardiac regeneration, cell delivery, Clinical Trials, Company Profiles, Cytori, Device-centric cell therapies, patient specific cell therapy, personalized medicine, Regenerative Medicine, stem cells | Leave a comment

Tengion Pioneers Autologous Tissue Engineered Regenerative Medicine Products

Posted on January 29, 2008 by jrowley

You have to hand it to Tengion, they are trying to tackle one of the largest challenges I can think of: producing tissue engineered organs and tissues from a patients own cells in unrelated indications (bladder, blood vessel, and kidney). … Continue reading →

Posted in autologous, Biomaterials, Bioprocessing, Clinical Trials, combination products, Company Profiles, JNJ, patient specific cell therapy, personalized medicine, Regenerative Medicine, Tengion, tissue engineered product, vascular regeneration | Tagged , , | 3 Comments

Pervasis Advances Tissue Engineered Products for Vascular Health

Posted on January 22, 2008 by jrowley

Pervasis Therapeutics announced that they have raised $9.75M to further develop their allogenic tissue engineered endothelial cell (EC) product for vascular health indications. Their Vascugel product is comprised of ECs grown in 3D collagen sponges that are implanted externally on … Continue reading →

Posted in Biomaterials, Bioprocessing, cell delivery, Clinical Trials, combination products, Company Profiles, Manufacturing, Pervasis, Regenerative Medicine, tissue engineered product, vascular regeneration | Tagged , , , , , | 1 Comment

Consolidation Trends Within the Blossoming RegenMed Service Sector

Posted on January 9, 2008 by jrowley

The WuXi acquisition of Apptec (posted last week) is continuing the trend of consolidation in the cell manufacturing sector. It is similar to Lonza’s (a Swiss company) purchase of Cambrex’s biologics division in 2006, and GE’s purchase of Wave Biotech … Continue reading →

Posted in Apptec, BD, Bioprocessing, Invitrogen, JNJ, Lonza, Manufacturing, Progenitor Cell Therapy, Regenerative Medicine, Stem Cells Inc, WuXi Pharmatech | 1 Comment

Chinese CRO WuXi Pharmatech Acquires Apptec Laboratory Services

Posted on January 7, 2008 by jrowley

WuXi (pronounced Woo-See) Pharmatech, a contract research organization (CRO) based in China, announced the acquisition of MN-based Apptec Laboratory Services. WuXi acquired Apptec to gain an immediate US footprint, better access to the US market, and important biologics expertise to … Continue reading →

Posted in Apptec, BD, Bioprocessing, business models, Company Profiles, Invitrogen, JNJ, Lonza, Manufacturing, Regenerative Medicine, WuXi Pharmatech | 1 Comment

BioTime Births Embryome Sciences

Posted on December 19, 2007 by jrowley

There have been some interesting news releases this week, including Osiris’ fast track designation, Cytori obtaining a 510k for their fat cleaner (not their stem cell isolation device, just a clinical fat cleaner), and the angiogenesis and liver regeneration capabilities … Continue reading →

Posted in Bioprocessing, BioTime, business models, Embryome Sciences, Regenerative Medicine | Tagged , , , , , | Leave a comment

Organogenesis Expands into China

Posted on December 13, 2007 by jrowley

Organogenesis, one of the pioneering tissue engineering companies, is partnering with China’s National Tissue Engineering Center (NTEC) to bring Organogenesis’ regenerative therapies to the Chinese marketplace. NTEC is a Shanghai-based private company that is funded by the Chinese government, and … Continue reading →

Posted in Bioprocessing, business models, Joint Ventures, Manufacturing, Regenerative Medicine | Tagged , , , , | 1 Comment

Jobs in Regenerative Medicine: Part I

Posted on December 13, 2007 by jrowley

One of the aspects of my science career that I really enjoy is the career coaching that I provide, and receive. I actually spend a lot of time telling students that are graduating, whether it is at the Bachelors, Masters, … Continue reading →

Posted in Bioprocessing, Job search, Regenerative Medicine | Tagged , , , , | 5 Comments

Progenitor Cell Therapy, LLC: Acquisition Target

Posted on December 4, 2007 by jrowley

I have been playing with the idea of a post related to the area of therapeutic cell bioprocessing, and today one of the leaders in the field became an acquisition target. Progenitor Cell Therapy (PCT) provides process development and manufacturing … Continue reading →

Posted in Bioprocessing | Leave a comment